BRPI0406812A - Combinação farmacêutica para a profilaxia ou terapia de doenças cardiovasculares, cardiopulmonares, pulmonares ou renais - Google Patents

Combinação farmacêutica para a profilaxia ou terapia de doenças cardiovasculares, cardiopulmonares, pulmonares ou renais

Info

Publication number
BRPI0406812A
BRPI0406812A BR0406812-2A BRPI0406812A BRPI0406812A BR PI0406812 A BRPI0406812 A BR PI0406812A BR PI0406812 A BRPI0406812 A BR PI0406812A BR PI0406812 A BRPI0406812 A BR PI0406812A
Authority
BR
Brazil
Prior art keywords
therapy
cardiopulmonary
prophylaxis
pulmonary
cardiovascular
Prior art date
Application number
BR0406812-2A
Other languages
English (en)
Inventor
Axel Riedel
Josep-Maria Sendra
Josef M E Leiter
Stefan Kauschke
Michael Mark
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10301372A external-priority patent/DE10301372A1/de
Priority claimed from DE10335027A external-priority patent/DE10335027A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BRPI0406812A publication Critical patent/BRPI0406812A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMBINAçãO FARMACêUTICA PARA A PROFILAXIA OU TERAPIA DE DOENçAS CARDIOVASCULARES, CARDIOPULMONARES, PULMONARES OU RENAIS". A presente invenção refere-se a um processo para a profilaxia ou terapia de doenças cardiovasculares, cardiopulmonares, pulmonares ou renais pela melhora da função endotelial e obtenção de uma proteção de órgãos, tecidos e vasos em indicações, nas quais é necessário um controle da pressão arterial e um controle do nível de lipídeos, particularmente de pessoas nas tais foi diagnosticado diabetes melito do tipo 2 ou há suspeita de pré-diabetes, para a prevenção de diabetes e pré-diabetes ou para o tratamento da síndrome metabólica e da resistência à insulina em pacientes com pressão arterial normal. O processo abrange a administração comum de quantidades eficazes de telmisartan ou de um polimorfo ou sal do mesmo e simvastatina. Além disso, a invenção refere-se a composições farmacêuticas, que contêm telmisartan ou um polimorfo ou sal do mesmo e simvastatina, como preparado de combinação para a aplicação simultânea, separada ou seq³encial na profilaxia ou terapia dessas doenças.
BR0406812-2A 2003-01-16 2004-01-14 Combinação farmacêutica para a profilaxia ou terapia de doenças cardiovasculares, cardiopulmonares, pulmonares ou renais BRPI0406812A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10301372A DE10301372A1 (de) 2003-01-16 2003-01-16 Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
DE10335027A DE10335027A1 (de) 2003-07-31 2003-07-31 Verwendung von Angiotensin II Rezeptor Antagonisten
PCT/EP2004/000175 WO2004062729A1 (de) 2003-01-16 2004-01-14 Pharmazeutische kombination zur prophylaxe oder therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen krankheiten

Publications (1)

Publication Number Publication Date
BRPI0406812A true BRPI0406812A (pt) 2005-12-27

Family

ID=32714792

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406812-2A BRPI0406812A (pt) 2003-01-16 2004-01-14 Combinação farmacêutica para a profilaxia ou terapia de doenças cardiovasculares, cardiopulmonares, pulmonares ou renais

Country Status (22)

Country Link
US (2) US20050004193A1 (pt)
EP (2) EP1818056A1 (pt)
JP (1) JP2006515877A (pt)
KR (1) KR20050092119A (pt)
AT (1) ATE362782T1 (pt)
AU (1) AU2004204353A1 (pt)
BR (1) BRPI0406812A (pt)
CA (1) CA2513281C (pt)
CY (1) CY1106775T1 (pt)
DE (1) DE502004003880D1 (pt)
DK (1) DK1587584T3 (pt)
EA (1) EA009886B1 (pt)
EC (1) ECSP055914A (pt)
ES (1) ES2287689T3 (pt)
HR (1) HRP20050655A2 (pt)
MX (1) MXPA05007559A (pt)
NO (1) NO20053793L (pt)
PL (1) PL376213A1 (pt)
PT (1) PT1587584E (pt)
RS (1) RS20050536A (pt)
SI (1) SI1587584T1 (pt)
WO (1) WO2004062729A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
PL1814527T5 (pl) * 2004-11-05 2021-08-02 Boehringer Ingelheim International Gmbh Dwuwarstwowa tabletka zawierająca telmisartan i amlodypinę
WO2007051007A2 (en) * 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
US20090030057A1 (en) * 2005-11-22 2009-01-29 Shlomit Wizel Pharmaceutical composition of telmisartan
JP5558104B2 (ja) * 2006-12-11 2014-07-23 スリー−ディー マトリックス， インコーポレイテッド 心組織の保護および再生のための組成物および方法
KR101209319B1 (ko) 2008-04-29 2012-12-06 한올바이오파마주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
WO2010075347A2 (en) * 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
EP2787993B1 (en) * 2011-12-09 2016-11-23 Artskin D.O.O. TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
WO2013136277A1 (en) * 2012-03-13 2013-09-19 Unimark Remedies Ltd. Pharmaceutical compositions for treatment of cardiovascular diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ330774A (en) * 1996-04-05 1999-06-29 Takeda Chemical Industries Ltd Pharmaceutical composition having angiotensin ii antagonistic activity or salt thereof with an insulin-sensitivity increasing compound and postprandial hyperglycemia in diabetes mellitus and antagonistic activity and increased insulin-sensitivity
US20010006656A1 (en) * 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
DK1216038T3 (da) * 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
US20040023840A1 (en) * 2000-04-12 2004-02-05 Marc De Gasparo Combination of organic compounds
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
EP1314425A4 (en) * 2000-08-30 2004-06-02 Sankyo Co MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
JP4585198B2 (ja) * 2002-12-27 2010-11-24 武田薬品工業株式会社 体重増加抑制剤

Also Published As

Publication number Publication date
MXPA05007559A (es) 2005-09-21
CA2513281C (en) 2012-04-03
US20110190277A1 (en) 2011-08-04
RS20050536A (sr) 2007-09-21
CA2513281A1 (en) 2004-07-29
SI1587584T1 (sl) 2007-10-31
ECSP055914A (es) 2006-03-01
HRP20050655A2 (en) 2006-05-31
EA009886B1 (ru) 2008-04-28
EP1818056A1 (de) 2007-08-15
EA200501057A1 (ru) 2006-02-24
KR20050092119A (ko) 2005-09-20
US20050004193A1 (en) 2005-01-06
PT1587584E (pt) 2007-06-11
EP1587584A1 (de) 2005-10-26
DE502004003880D1 (de) 2007-07-05
NO20053793L (no) 2005-08-10
CY1106775T1 (el) 2012-05-23
PL376213A1 (en) 2005-12-27
ES2287689T3 (es) 2007-12-16
WO2004062729A8 (de) 2004-10-07
ATE362782T1 (de) 2007-06-15
EP1587584B1 (de) 2007-05-23
AU2004204353A1 (en) 2004-07-29
JP2006515877A (ja) 2006-06-08
DK1587584T3 (da) 2007-09-24
WO2004062729A1 (de) 2004-07-29

Similar Documents

Publication Publication Date Title
Dolinsky et al. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice
Toussaint et al. The evaluation and management of thermal injuries: 2014 update
Ikeda et al. Mitochondria-targeted hydrogen sulfide donor AP39 improves neurological outcomes after cardiac arrest in mice
CY1106775T1 (el) Φαρμακευτικος συνδυασμος για την προληψη ή θεραπεια καρδιαγγειακων, καρδιοπνευμονικων πνευμονικων ή νεφρικων παθησεων
Kennedy et al. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months
BRPI0718596B8 (pt) composições farmacêuticas para terapia de combinação com inibidores de sglt-2 e metformina
Huang et al. Acute lung injury in patients with severe acute pancreatitis
UA84282C2 (ru) Применение телмисартана и аторвастатина для лечения сахарного диабета типа іі и фармацевтическая композиция
Pei et al. Normobaric hyperoxia plays a protective role against renal ischemia-reperfusion injury by activating the Nrf2/HO-1 signaling pathway
Chen et al. Anti-stiffness effect of apocynin in deoxycorticosterone acetate-salt hypertensive rats via inhibition of oxidative stress
Scherrer et al. High altitude, a natural research laboratory for the study of cardiovascular physiology and pathophysiology
ES2229514T3 (es) Composicion que comprende l-carnitina o una alcanoil-l-carnitina y alcanoles de cadena larga.
Yeh et al. Curcumin attenuates hemorrhagic shock and blood replenish resuscitation-induced impairment of pulmonary barrier function by increasing SIRT1 and reducing malondialdehyde and TNF-α contents and neutrophil infiltration in lung in a dose-dependent fashion
Sabarimuthu et al. Diosmin prevents left ventricular hypertrophy, adenosine triphosphatases dysfunction and electrolyte imbalance in experimentally induced myocardial infarcted rats
Noh et al. Sglt2 inhibitors as systemic metabolic modulators: Linking glucose excretion to liver function restoration
Tilelli et al. Life‐Threatening Bradyarrhythmia After Massive Azithromycin Overdose
BR112013009043A2 (pt) composto, uso de um composto, e, método para tratar uma doença
Carbone et al. SGLT2 inhibition, visceral adiposity, weight, and type 2 diabetes mellitus
Bannet et al. Clinical aspects of the interaction of lithium and stimulants
Zhou Pyruvate Potentially Superior to NAD and Senolytics in Healthy Aging
Kuznetsova et al. EFFICACY OF USING MELOXICAM IN THE TREATMENT OF OSTEOARTHRITIS IN PATIENTS WITH COMORBID PATHOLOGY
Mustapha et al. Chemical chaperone TUDCA rescues Insulin-mediated vascular relaxation via ER stress inhibition in diabetic rat model
Shepard The Impact of Diabetes Mellitus on Burns and Standard Burn Treatments
Guo et al. Giant R waves on electrocardiogram in children with asphyxia after cardiopulmonary resuscitation: Two case reports
Trikha et al. A case of myocarditis mimicking myocardial infarction in hair dye poisoning

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/41 (2006.01), A61P 9/10 (2006.01), A61K 31